인도의 핵의학 영상 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the india nuclear imaging market size is expected to grow from USD 422.19 million in 2025 to USD 459.72 million in 2026 and is forecast to reach USD 703.69 million by 2031 at 8.89% CAGR over 2026-2031.

This report is Segmented by Product (Equipment, Radioisotopes [SPECT Radioisotopes {Technetium-99m (Tc-99m), and More} and PET Radioisotopes]), Application (Cardiology, Neurology, Thyroid, Oncology, and Other Applications), End User (Hospitals, Diagnostic Imaging Centres, and Academic & Research Institutes). The Market Forecasts are Provided in Terms of Value (USD).

India Nuclear Imaging Market Trends and Insights

Growing Prevalence of Cancer and Cardiac Diseases

India logged 1.4 million new cancer cases in 2024, and the National Cancer Registry projects a 12.8% jump by 2025. Late-stage diagnosis remains common, with only 29% of tumors detected early, raising demand for precise PET and SPECT procedures that can delineate disease spread. Nuclear cardiology volumes are climbing as coronary artery disease afflicts younger cohorts; two-thirds of Indians aged 25-45 are now pre-hypertensive, prompting clinicians to choose non-invasive myocardial perfusion imaging to triage intervention. Rising lifestyle-related morbidity therefore directly boosts utilization across all nuclear imaging modalities, reinforcing the structural growth of the India nuclear imaging market.

Adoption of Hybrid PET-CT and SPECT-CT in Tertiary Hospitals

PET-CT installations have surpassed 50 units nationwide while SPECT-CT growth trails because of higher per-scan costs. However, cost-effectiveness studies show a PET-CT scan in India is priced at INR 4,600-31,000 (USD 55-372), far below global averages, shortening payback periods for large centers. CZT detectors and AI-assisted reconstruction improve resolution while lowering tracer dose, making hybrid imaging more attractive in radiation-safety-conscious facilities. As tertiary hospitals upgrade equipment, referral patterns shift toward comprehensive nuclear imaging suites, which further enlarges the India nuclear imaging market.

High Equipment Acquisition and Maintenance Cost

Setting up a gamma-knife or PET-CT suite can cost INR 400 million (USD 4.88 million) when real estate, shielding, and licensing expenses are included. Smaller hospitals often lack patient throughput to justify such outlays, so metropolitan tertiary centers remain the primary installation sites, limiting geographic penetration of the India nuclear imaging market. Post-warranty service contracts priced at 8-10% of capital value per year strain operating budgets, particularly since spare parts are imported and dollar-denominated. Leasing programs and public-private partnerships are emerging, yet they remain nascent and do not fully erase the high-capex hurdle.

Other drivers and restraints analyzed in the detailed report include:

1. Ayushman Bharat Imaging-Infrastructure Roll-out
2. Expansion of Domestic Radioisotope Production at BARC
3. Scarcity of Skilled Nuclear-Medicine Technologists

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Radioisotopes generated 59.78% of the India nuclear imaging market share in 2025, and the subsegment is forecast to post a 9.62% CAGR through 2031. Technetium-99m remains the workhorse for SPECT, accounting for roughly 80% of single-photon studies, yet its reactor-based production chain presents well-documented supply risk. PET radioisotopes such as Fluorine-18 are growing more swiftly, aided by new cyclotrons in Chennai and Hyderabad that reduce tracer decay losses during transport. On the therapeutic front, Lutetium-177 labeled compounds for neuroendocrine tumors and prostate cancer secured Drug Controller General of India approvals in 2024, spurring wider adoption. Domestic Lu-177 output at BARC meets 65% of national demand, trimming procedure costs by nearly 20% versus imported doses.

The equipment segment adds incremental value through hardware innovation, especially solid-state detector arrays that boost sensitivity in low-dose scans. Localization initiatives by GE HealthCare and Siemens Healthineers promise to shave 10-12% off unit prices by 2027, but maintenance costs remain elevated because high-precision crystals and vacuum components still come from overseas. Even so, rising equipment affordability broadens the customer base, supporting a virtuous cycle of radioisotope demand that further scales the India nuclear imaging market size.

List of Companies Covered in this Report:

1. Advanced Accelerator Applications S.A. (Novartis)
2. Alliance Medical (Life Healthcare Group)
3. Board of Radiation & Isotope Technology (BRIT)
4. Bracco Imaging S.p.A.
5. Canon
6. Cardinal Health
7. Curium Pharma
8. GE Healthcare
9. Koninklijke Philips
10. Positron
11. Shenzen Mindray Bio-Medical Electronics Co., Ltd.
12. Siemens Healthineers

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing prevalence of cancer and cardiac diseases
  • 4.2.2 Rising adoption of hybrid imaging modalities in tertiary hospitals
  • 4.2.3 Government initiatives under Ayushman Bharat to expand imaging infrastructure
  • 4.2.4 Increasing domestic radioisotope production via BARC
  • 4.2.5 Shift to low-dose CZT detectors driven by radiation-safety norms
  • 4.2.6 Emergence of private-equity-funded standalone PET-CT chains
• 4.3 Market Restraints
  • 4.3.1 High cost of equipment acquisition and maintenance
  • 4.3.2 Scarcity of skilled nuclear-medicine technologists
  • 4.3.3 Mo-99 import supply-chain disruptions
  • 4.3.4 AERB licensing delays for new cyclotrons
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product
  • 5.1.1 Equipment
  • 5.1.2 Radioisotopes
    • 5.1.2.1 SPECT Radioisotopes
      • 5.1.2.1.1 Technetium-99m (Tc-99m)
      • 5.1.2.1.2 Thallium-201 (Tl-201)
      • 5.1.2.1.3 Gallium-67 (Ga-67)
      • 5.1.2.1.4 Iodine-123 (I-123)
      • 5.1.2.1.5 Other SPECT Isotopes
    • 5.1.2.2 PET Radioisotopes
      • 5.1.2.2.1 Fluorine-18 (F-18)
      • 5.1.2.2.2 Rubidium-82 (Rb-82)
      • 5.1.2.2.3 Other PET Isotopes
• 5.2 By Application
  • 5.2.1 Cardiology
  • 5.2.2 Neurology
  • 5.2.3 Thyroid
  • 5.2.4 Oncology
  • 5.2.5 Other Applications
• 5.3 By End User
  • 5.3.1 Hospitals
  • 5.3.2 Diagnostic Imaging Centres
  • 5.3.3 Academic & Research Institutes

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Advanced Accelerator Applications S.A. (Novartis)
  • 6.3.2 Alliance Medical (Life Healthcare Group)
  • 6.3.3 Board of Radiation & Isotope Technology (BRIT)
  • 6.3.4 Bracco Imaging S.p.A.
  • 6.3.5 Canon Medical Systems Corporation
  • 6.3.6 Cardinal Health Inc.
  • 6.3.7 Curium Pharma
  • 6.3.8 GE HealthCare
  • 6.3.9 Koninklijke Philips N.V.
  • 6.3.10 Positron Corporation
  • 6.3.11 Shenzen Mindray Bio-Medical Electronics Co., Ltd.
  • 6.3.12 Siemens Healthineers

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment